CUF Porto Hospital

Porto 4100-180

1 studies enrolling now · 3 studies all time

What they study most

Advanced Cholangiocarcinoma, Anaplastic Lymphoma Kinase-positive, Carcinoma, Non-Small-Cell Lung, FGFR2 Gene Rearrangements, Non-small Cell Lung Cancer

Studies at this site

• Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC — Recruiting now
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — Stopped early
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer — Stopped early